Jakob Buecheler joined Novartis in January 2019 as part of the Advanced Manufacturing and Technologies group with the focus on Drug Product Technologies. He joined from Merck KGaA, where he was working on Antibody-Drug Conjugates as part of his PhD with the focus on degradation pathways and formulation aspects. He holds a BSc. in Biology from the University of Mainz, Germany and a MSc. in Microbiology from the University of Tuebingen, Germany. He further had research engagements at the University of Queensland, Australia and the Nanyang Technological University, Singapore in the field of Bioengineering as well as at Hoffmann-La Roche, Switzerland at the Department of Pharmaceutical Development.
Advanced Manufacturing and Technologies Group